Gossamer Bio (NASDAQ:GOSS) Executes 80-for-1 Reverse Stock Split

• Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on developing treatments for serious conditions like pulmonary arterial hypertension.
• The company recently executed an 80-for-1 reverse stock split to consolidate outstanding shares and typically increase the price per share.
• Post-split, Gossamer Bio has a market capitalization of approximately $5.33 billion with a daily trading volume of around 139,079 shares.

Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company. It focuses on developing and selling seralutinib. This treatment is for serious conditions like pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company operates in a highly specialized area of medicine.

On September 11, 2026, Gossamer Bio executed an 80-for-1 reverse stock split. A reverse stock split reduces the total number of a company's outstanding shares. This action consolidates shares and typically increases the price per share without changing the company's total value.

The company's board of directors approved the split, as highlighted by Business Wire. To make it official, Gossamer Bio filed a Certificate of Amendment in Delaware. The split became effective at 11:59 p.m. Eastern Time on September 10, 2026, with shares trading on a split-adjusted basis afterward.

Following the split, Gossamer Bio shares are priced at $10.91, a decrease of 4.23% for the day. The stock's price has moved between $10.57 and $12.52 during the trading session. Over the last 52 weeks, the share price has seen a high of $309.60 and a low of $9.10.

Gossamer Bio has a market capitalization of approximately $5.33 billion. Market capitalization is the total value of all a company's shares of stock. The daily trading volume is around 139,079 shares, which shows the number of shares being bought and sold.